AbbVie Must Pay $150M For False AndroGel Ads, Jury Says

Law360, Chicago (July 24, 2017, 2:16 PM EDT) -- An Illinois federal jury on Monday found that AbbVie Inc. isn't liable for an AndroGel user's heart attack but ordered the company to pay $150 million in punitive damages for funding ads that misrepresented what the testosterone replacement therapy drug could treat.

Monday's verdict is the first in the multidistrict litigation over testosterone gel products concentrated in Illinois federal court. Shown is a computer display at an unrelated 2007 arbitration hearing in California. (AP) The award is an unusual ending to a three-week trial over claims the company ignored a connection between AndroGel and heart attacks while promoting it to treat...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!